

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  C12N 15/85, C12Q 1/68		A1	(11) International Publication Number: <b>WO 99/66060</b>  (43) International Publication Date: 23 December 1999 (23.12.99)
<p>(21) International Application Number: PCT/IB99/01071</p> <p>(22) International Filing Date: 11 June 1999 (11.06.99)</p> <p>(30) Priority Data: 10/170941 18 June 1998 (18.06.98) JP</p> <p>(71) Applicant (for all designated States except US): HOECHST MARION ROUSSEL LTD. [JP/JP]; 17-51, Akasaka 2-chome, Minato-ku, Tokyo 107-8465 (JP).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): KAWAI, Shinji [JP/FR]; 416, rue Emile Dubois, F-75014 Paris (FR). SUGIURA, Takeyuki [JP/JP]; 4-4-22-202, Kamishakuji-i, Nerima-ku, Tokyo 177-0044 (JP). HÖTTEN, Gertrud [DE/DE]; Hölkenskampring 96, D-44625 Herne (DE).</p> <p>(74) Agent: VIEILLEFOSSE, Jean-Claude; Hoechst Marion Roussel, 102, route de Noisy, F-93235 Romainville Cedex (FR).</p>		<p>(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>	
<p>(54) Title: HUMAN MP52 GENE PROMOTER AND METHOD FOR EXPLORING USEFUL SUBSTANCE BY USING THE SAME</p> <p style="text-align: center;"> </p> <p style="text-align: right; font-size: 2em; transform: rotate(-45deg);">BEST AVAILABLE COPY</p> <p>(57) Abstract</p> <p>The present object is to provide a method for exploring low molecular weight compounds having osteogenic activity or an activity to inhibit osteogenesis that shows an equal degree to human BMP proteins. A method for exploring low molecular weight compounds which regulate positively or negatively the expression of human MP52 with reference to a reporter activity by using 5' upstream region gene containing the human MP52 promoter and an animal cell into which a recombinant expression vector that has been ligated to an appropriate reporter gene has been introduced. Low molecular weight compounds and their derivatives obtained by the present method have morphogenetic activity and inhibiting activity for bone and cartilage, inducing or inhibiting activity for tendon and ligament, forming, inducing, and protecting effects on neural cells, or inducing or inhibiting angiogenic activity, and are effective as preventive or therapeutic agent for cartilage and bone diseases, therapeutic agent for injury of tendon and ligament, therapeutic agent for neural diseases, or healing agent for injury and carcinostatic, through the expression of human MP52.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HUMAN MP52 GENE PROMOTER AND METHOD FOR EXPLORING USEFUL  
SUBSTANCE BY USING THE SAME

BACKGROUND OF THE INVENTION

5 (1) Field of the Invention

The present invention relates to a 5' upstream region DNA sequence which contains a promoter of human MP52 gene. Furthermore, the present invention provides a method for exploring low molecular weight compound regulating positively 10 or negatively the expression of human MP52 by using a mass of animal cells transfected with a recombinant expression vector harboring the 5' upstream region DNA containing the human MP52 gene promoter in front of a suitable reporter gene, and by using a reporter activity as an indicator.

15 (2) Description of the Related Art

Many substances have been known as usable for healing of bone deficit or fracture, by enhancing bone regeneration. Among them, a bone morphogenetic protein (BMP, hereafter) is a protein belonging to TGF (transforming growth factor) 20 - $\beta$  superfamily and has been formerly found as a substance inducing ectopic ossification and existing in decalcified bone tissue (Trends in Biotechnol. 11, 379-383, 1993). BMP members known so far range from BMP-1 to BMP-14. Among them, the members from BMP-2 to BMP-14 have been known as showing 25 the bone morphogenetic activity.

Human MP52 is a BMP-like protein isolated by PCR cloning (Biochem. Biophys. Res. Comm. 204, 646-652, 1994). Recombinant human MP52 has been reported as effective not only in inducing ectopic ossification, but also in curing 30 bone deficit in an animal model (Growth Factors 13, 65-74, 1996).

It is considered that these BMP proteins are effective in treating and preventing various bone disorders and bone diseases. However, the BMP proteins exist in very small 35 quantity in nature, and for an available large quantity for therapeutic use, manufacturing a recombinant protein is necessary.

Preparing a recombinant protein is generally very

expensive compared with low molecular weight compounds. Furthermore, there are many restrictions as a medicinal drug in terms of physical properties and administration methods due to proteineous characteristics. Considering these 5 points, a small molecular organic compound having the activity equal to that of the BMP proteins described above, if any, should be a highly promising medicinal drug.

#### SUMMARY OF THE INVENTION

The present invention provides a method for exploring a 10 substance which induces human MP52, a BMP-like protein. A useful substance obtained by this exploring method can be effective in inducing expression of human MP52, a bone formation factor. Since it has a small molecular weight and the same activity as that of human MP52, it can have a very 15 useful application. On the contrary, the present invention provides a method for exploring a substance which inhibits expression of human MP52. In case that human MP52 relates to bone and cartilage hyperplasia, it can prevent hyperplasia by inhibiting the expression of human MP52.

20 Recently, it has been suggested that a mutant of the human MP52 protein not only decreases the activity per se, but also deactivates other BMPs by forming dimer proteins (Nature Genetics, 17, 58-64, 1997). The substance inhibiting the expression of human MP52 may be effective in mitigating 25 chondrodystrophy caused by such a mutant MP52.

Moreover, it has been known that human MP52 has a tendon and ligament inducing activity (Toshiyuki Tashiro et al., American Society of Bone and Mineral Research, F336, 1997), neural cells forming, inducing, and protecting effects (J. 30 Neurosci. Res., 42, 724-732, 1995), and angiogenic activity (Exp. Cell Res., 235, 218-226, 1997). Thus, it is possible that the exploring method provided by the present invention gives tendon and ligament inducing and inhibiting substances, neural inducing substances, or pro- and anti-angiogenic 35 substances.

For such an exploring method, an example was so far only reported using a mouse BMP-2 promoter (W097/15308); there is no example of using the human MP52 promoter. In addition,

since the materials of the exploring method provided by the present invention are all derived from human sources, it can be expected that the discovered compounds should show the clinical effects.

##### 5 BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a 3.5 kb of 5' upstream region of human MP52 gene and a restriction enzyme map.

Fig. 2 is a recombinant expression vector (pMP52L) containing a 5' upstream region of human MP52 gene. A 10 fragment, base No. from 1 to 3227 (Apal position 1) shown in SEQ ID NO.: 1 of the Sequence Listing, was inserted to the restriction enzyme site, *HindIII-KpnI*, of pGL3-basic.

Fig. 3 is a result of measuring a human MP52 promoter activity (transient expression). pGL3B means pGL3-basic in 15 the figure.

##### DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention relates to a DNA whose nucleotide sequence is represented by the base sequence from No. 1 to No. 3521 in SEQ ID NO.: 1 of the Sequence Listing that 20 encodes a human MP52 gene promoter region, or a fragment thereof. SEQ ID NO.: 1 of the Sequence Listing shows a 5' upstream region sequence of the human MP52 gene.

The present invention relates to a method for preparing the DNA shown in SEQ ID NO.: 1 of the Sequence Listing having 25 the steps of:

- (1) preparation of a cDNA probe by PCR with a degenerate primer,
- (2) plaque hybridization screening of a human genomic phage library by using the probe, and
- 30 (3) subcloning of a target fragment from an isolated phage clone.

The plasmid vector used here is not restricted and any commercialized vector can be used. A preferable example is PUC18.

35 The present invention relates to a recombinant expression vector characterized by integration of the full length or a part of DNA shown in SEQ ID NO.: 1 of the Sequence Listing into a reporter gene. In detail, the

recombinant expression vector is constructed to locate a suitable region of 5' upstream region of the human MP-52 gene, that is represented by SEQ ID No.: 1 of the Sequence Listing, in front of a reporter gene. The reporter gene such 5 as luciferase or  $\beta$ -galactosidase gene shows an expressing status on behalf of an original product. The basic vector for constructing the recombination expression vector is not specially restricted to allow to use a plasmid vector commercialized. The present invention uses pGL3-basic as a 10 preferable example. The use of pGL3-basic yielded a pMP52L (8085 bp) that is a recombination vector containing the human MP52 promoter and a luciferase reporter gene. The present invention assigned it to a recombination expression vector. It is necessary to introduce the vector, to mammalian cells, 15 preferably a human osteoblast-like cells, such as SaOS-2 cells, with a liposome. The animal cells stably transfected with the recombinant expression vector are selected by using a resistance marker.

The present invention relates to an exploring method for 20 a useful substance by using a recombinant expression vector characterized by integrating the full length or a part of DNA shown in SEQ ID NO.: 1 of the Sequence Listing into a reporter gene. The sequence from 2880 to 3521 in SEQ ID NO.: 1 of the Sequence Listing has been already reported (Biochem. 25 Biophys. Res. Comm., 204, 646-652, 1994). The longer sequence has been integrated in a recombinant expression vector, the more natural process of the exploring method can be used. The present invention relates to the method for exploring a useful substance which is a bone-related 30 substance. In particular, the present invention relates to the method for exploring a useful substance which is an osteogenesis inducing substance or which is an osteogenesis inhibiting substance. Furthermore, the present invention relates to the method for exploring a useful substance which 35 is a neurogenic substance or which is an angiogenic substance. A low molecular weight compound which induces or inhibits the expression of human MP52 can be obtained by isolating the promoter which regulates the expression of the

gene, by ligating it to a suitable reporter gene and by introducing the gene structure into a suitable mammal cell to make an exploring system. The substance which regulates the expression of human MP52 in the exploring system works on the 5 promoter to increase or decrease the expression level of the reporter gene. Therefore, a simple and easy measurement of the reporter activity makes an exploration of the aimed possible substance.

The animal cell transfected with said vector can be used 10 for a method for screening a chemical compound library by high throughput screening (Nature, 384, supp, 14-16, 1996) and finding an active substance from natural compounds. The substance which increases or decreases an activity is searched by treating the cell with a compound for an 15 appropriate period of time and measuring a reporter activity. The compound obtained in such a way can regulate the expression by working directly on a transcription factor or indirectly on the promoter of human MP52 through regulating a signal transduction system. Therefore, these compounds are 20 effective as a therapeutic agent for osteocartilaginous diseases, cancer metastasis to bone, or osteohyperplasia. As other examples, these compounds are effective as a recovering agent for tendon and ligament injuries, a remedy for neural diseases, or an angiogenesis inducing or inhibiting agent.

25 The substance obtained by the present invention has a bone or cartilage morphogenetic activity and is effective as an agent for therapeutic and preventive treatment in the field of orthopedic surgery (fracture, osteoarthritis such as joint osteoarthritis and hip joint osteoarthritis, 30 arthrosteitis, damage of cartilage such as damage of meniscus, regeneration of bone and cartilage deficit caused by injury and tumor dissection, bone reconstruction such as spinal fusion and vertebral canal enlargement, and congenital cartilage and bone diseases such as dysosteogenesis and 35 achondroplasia), or dental fields (bone reconstruction such as palatoschisis, mandible reconstruction, and residual ridge construction), and osteoporosis. Moreover, the substance of the present invention can be used for bone graft in aesthetic

surgery. These therapeutic treatments are effective in treating the field of veterinary surgery. On the other hand, the present invention can provide a substance which inhibits bone or cartilage morphogenesis. In this case, the substance 5 is applied as an agent to prevention and therapy of bone or cartilage hyperplasia.

Moreover, the substance which induces or inhibits tendon and ligament can be obtained according to the present invention. Therefore, the present invention provides a 10 method for exploring medicinal drugs to treat damage of tendons and ligaments. Furthermore, since human MP52 has neural cells forming, inducing, and protecting effects, the compounds obtained from the present invention can be applied as therapeutic agents for neural diseases. In addition, it 15 is possible to obtain a substance inducing or inhibiting angiogenesis. The compounds obtained can be used as remedy for injury, carcinostatic and metastasis inhibitor.

By using 5' upstream region containing the human MP52 gene promoter and an animal cell into which a recombinant 20 expression vector that has been integrated in an appropriate reporter gene, low molecular weight compounds regulating positively or negatively the expression of human MP52 can be explored with reference to a reporter activity. Low molecular weight compounds and their derivatives have 25 morphogenetic activity and inhibiting activity for bone and cartilage through the expression of human MP52 and are useful as preventive or therapeutic agents for cartilage and bone diseases, remedies for osteometastasis, or therapeutic and preventive agents for osteohyperplasia. Furthermore, these 30 compounds are effective as repairing agent for injury of tendon and ligament, therapeutic agent for neural diseases, and inducing and inhibiting agent for angiogenesis.

#### EXAMPLES

This invention shall be more illustratively explained by 35 way of the following Examples. The following Examples are to be considered in all respects as illustrative and not restrictive.

Example 1 : Cloning of 5' upstream region of human MP52 gene

The 40 cycles of PCR reaction was carried out by using the primer OD of SEQ ID No.: 2 of the Sequence Listing and the primer OID of SEQ ID No.: 3 of the Sequence Listing, cDNA derived from a human fetus (8-9 week old) as a template, and 5 1.5 unit Taq polymerase (provided from Perkin Elmer Cetus). The following processes were repeated twice: the DNA amplified was treated with *Sph*I and *Alw*NI and then the PCR reaction was carried out 13 times. Finally, it was treated with *Eco*RI, the PCR product was ligated to pBluescript SK 10 (provided from Stratagene Ltd.). A human genomic phage library (provided from Stratagene Ltd.) was screened by plaque hybridization using the cDNA sequence of MP52 among cloned sequences. A 20 kb DNA obtained was subcloned to pBluescript SK vector, and an unnecessary part to remove was 15 cleaved by restriction with *Sal*I and *Bam*HI, to obtain the pBluescript vector containing a human MP52 DNA of 8.8 kb. The vector was named *E. coli* pMP52. *E. coli* pMP52 was deposited in National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, 20 Ministry of International Trade and Industry 1-3, Higashi 1-chome, Tsukuba-shi Ibaraki-ken 305-8566 Japan, in March 30, 1998 with depository No. FERM P-16734 and transferred to the International Depository Authority under Budapest Treaty on April 1, 1999 (Deposit No. FERM BP-6688).

25 **Example 2 : Determination of DNA sequence of 5' upstream region of human MP52 gene**

The pBluescript vector containing a human MP52 DNA of 8.8 kb was digested by *Xba*I, a remained large fragment (7.6 kb) was purified by agarose electrophoresis to subject to 30 self-ligation by using a ligation kit provided from Takara Shuzo Ltd. The 3.5 kb sequence of the 5' terminal was determined by using a vector containing the upstream region of the human MP52 gene of 4.7 kb as a template and by a ALF automated DNA sequencer (provided from Amersham Pharmacia Biotech Ltd.) (Proc. Natl. Acad. Sci. USA 74, 5463-5467, 35 1977). The 5' upstream region of the human MP52 gene consisting of 3521 bases is presented in SEQ ID No.: 1 of the Sequence Listing. Sequencing was done at least three times.

A site difficult to sequence was subcloned to sequence starting from both terminals. The base sequence from 2880 to 3521 shown in SEQ ID No.: 1 is already reported (Biochem. Biophys. Res. Comm. 204, 646-652, 1994).

5 **Example 3 : Construction of a recombinant vector containing the human MP52 gene promoter and a luciferase reporter gene**

The restriction enzyme map of the 5' upstream region 3.5 kb of human MP52 gene is shown in Fig. 1. An *Apa*LI-*Bgl*II fragment (0.6 kb) of the 5' upstream region of human MP52 10 gene was purified and the *Apa*LI end was blunted. Then, this fragment was treated with *Hind*III and *Bgl*II and inserted into a pGL3-basic vector of which *Hind*III end was blunted. The vector obtained was treated with *Bgl*II and *Kpn*I restriction enzymes to ligate to the *Bgl*II-*Kpn*I fragment (derived from 15 pBluescript vector) (2.7 kb) of the 5' upstream region of the human MP52 gene. The recombinant expression vector pMP52L (8085 bp) finally obtained contains 3.3 kb of 5' upstream region of human MP52 gene. Fig. 2 shows the constructed recombinant expression vector.

20 **Example 4 : Measurement of activity of the human MP52 promoter (introduction of the recombinant expression vector into human cells and transient expression)**

In order to transiently express the recombinant expression vector pMP52L of human MP52 promoter, said vector 25 was mixed with a vector pRL-SV40 (provided from Pro Mega Ltd.) containing a sea pansy luciferase gene as an internal control for measurement of introducing efficiency of a gene in an equal quantity. In addition, cationic liposome lipofectamine (provided from Lifetech Oriental Co.) was mixed 30 with said DNA solution to add to human osteosarcoma cells; HOS, MG63, or SaOS-2, for transfection. The fire fly luciferase activity and the sea pansy luciferase activity were measured by Pikka Gene Dual Kit (provided from Toyo Ink Co.). The result is shown in Fig. 3. The promoter activity 35 was expressed as a ratio of the fire fly luciferase activity to the sea pansy luciferase activity. From the result, it has been known that the DNA of SEQ ID No.: 1 of the Sequence Listing has a promoter activity.

**Example 5 : Introduction of the recombinant expression vector into human cells and stabilized expression**

In order to express stably the recombinant expression vector pMP52L of human MP52 promoter, said vector was mixed  
5 with a plasmid pPUR containing a gene resistant to puromycin in a proportion of 10 : 1, mixed with cationic liposome lipofectamine (provided from Lifetech Oriental Co.) and added to SaOS-2 cells for transfection. The cells into which the target gene has been introduced were selected from a culture  
10 medium containing puromycin (provided from Sigma Ltd.).

**Example 6 : Screening of active low molecular weight compound**

The cells selected were inoculated in a 96-well plate, treated with substances of various chemical compound libraries for 1 - 3 days, dissolved with cytolytic agent  
15 (provided from Pro Mega Ltd.), and measured for enzyme activity by employing a luciferase assay kit (provided from Pro Mega Ltd.). By such steps, various substances enhancing or inhibiting the expression of human MP52 can be surveyed.

10

## Sequence Listing Free Text

&lt;210&gt; 1

<223> Human MP52 5' upstream gene sequence ; the  
initiating codon ATG is located at the end of the  
sequence.

&lt;210&gt; 2

<223> Sense PCR primer OD corresponding to human MP52  
cDNA sequence

10

&lt;210&gt; 3

<223> Reverse PCR primer OID corresponding to human MP52  
cDNA sequence

What is claimed is:

1. A DNA whose nucleotide sequence is represented by the base sequence from No. 1 to No. 3521 in SEQ ID NO.: 1 of the Sequence Listing which encodes a human MP52 gene promoter region, or a fragment thereof.
2. A DNA whose nucleotide sequence is represented by the base sequence from No. 1 to No. 2879 in SEQ ID NO.: 1 of the Sequence Listing which encodes a human MP52 gene promoter region, or the fragment thereof.
3. A method for preparing the DNA shown in SEQ ID NO.: 1 of the Sequence Listing comprising the steps of:
  - (1) preparation of a cDNA probe by PCR with a degenerate primer,
  - (2) plaque hybridization screening of a human genomic phage library by using the probe, and
  - (3) subcloning of a target fragment from an isolated phage clone.
4. A recombinant expression vector characterized by integration of the full length or a part of DNA shown in SEQ ID NO.: 1 of the Sequence Listing into a reporter gene.
5. A method for exploring a useful substance, characterized by using the recombinant expression vector according to claim 4.
6. The method for exploring a useful substance according to claim 5, wherein the useful substance is a bone-related substance.
7. The method for exploring a useful substance according to claim 6, wherein the bone-related substance is an osteogenesis inducing substance.
8. The method for exploring a useful substance according to claim 6, wherein the bone-related substance is an osteogenesis inhibiting substance.
9. The method for exploring a useful substance according to claim 6, wherein the useful substance is a neurogenic substance.
10. The method for exploring a useful substance according to claim 6, wherein the useful substance is an angiogenic

12

substance.

11. The method for exploring a useful substance according to claim 6, wherein the useful substance is an anti-angiogenic substance.

5

1/3




FIGURE 1

2/3





FIGURE 2

*BEST AVAILABLE COPY*

3/3



BEST AVAILABLE COPY

FIGURE 3

1

## SEQUENCE LISTING

<110> Hoechst Marion Roussel Ltd

<120> Human MP52 gene promoter and method for exploring  
useful substance by using the same.

<130> JH98K006 PCT SEQUENCES IN ENGLISH

<140>

<141>

<150> 10-170941

<151> 1998-06-18

<160> 3

<170> PatentIn Ver. 2.1

<210> 1

<211> 3521

<212> DNA

<213> HUMAN

<220>

<221> misc\_feature

<222> (1)..(3521)

<223> Human MP52 5' upstream gene sequence ; the  
initiating codon ATG is located at the end of the  
sequence.

&lt;400&gt; 1

tcgactcgat cacttatgc aatttaattt tattttttt ttttagtagag acagggttcc 60  
accatgttag ccaggatggc cttgatctcc tgacctcggt atccacctgc ctgcgcctcc 120  
caaagtgcgt ggattacagg cgtgagcact ggcgcctggcc gcaatttact tcattgaatc 180  
tccaacaaga gtcctgtgag gtaagcacta tcgttatcac tggtagagt ttcaagaggg 240  
tttagaggct tcccaagatc acacaataca taaatagcag aaccaagctt caaaaccagg 300  
tctgtttgtc tccagaatcc ttgctttta tcaagccacg tacagagaca ttgtgggtgt 360  
tcaactcatt catttattca ctctctgagc ttacaaaatg cttaagaagt ggcaagacaa 420  
ttcttccctt caagaaaactt agagtctaattt gggaaaggca ggttatgtcc acaaataact 480  
acacctcaaa gtagaaaaatg atgatttttgc tcaataaggg ccagtttagag attaatttat 540  
tcataataaca cgtactgaga gctgctgtgg gctgggcctc tgccaagcac tgggtataat 600  
tcaaagataa atatggcaca gtctagtcattt aatctaattgg gagagacagg tatgtaaaga 660  
aattattata gttataagga attaagttt gattttaaaa tatgacaaaa tacagagtgg 720  
aagaaacaaa ctgtgttggg atagggggca gaggcagaga ctgaataaac tttcagctgc 780  
caaaaaatgt aaaagagcac agaaaatgtg tgatggcagc tcagggggag tgcatttt 840  
ctggaggatg caagaaggct tcatggagga ggtggcacgt ggttggcac ttgtttgatg 900  
ggtagctttt agtagagggt tgaaccagag agagcctggc ggcctagaag ccagttata 960  
gggagaatca tagcgaggca agcaatgagg aggacaggc agtgacagag gtggtgagga 1020  
ttttttatattt tattaatattt atttatttac ttattttgtg tgcgtgtatgg gactctagc 1140  
tctgtcacct aggctggagt gcagtggtgc gatctcggt cactgcaacc ttgcctcca 1200  
cacccggcta atttttgttta tttttggtag agatgcctgc aatcccagca ctggagagg 1260  
ccaagggtggg tggatcactt gaggtcagga gctcgagacc agactggcca acatggtaa 1320  
actccgtctc tactaaaaat acaaaaaata gataggcatg gtgggtgtca cctgttagtcc 1380  
cagctactcg agaggctgag gcaggagaat cggttgaacc caggaggtgg agattacagt 1440  
gagccaagat cgccaccactg cactccagcc tagtgacag agtgagactc tgcgtcaaaa 1500  
aaaaaaaaaaaa aaaaaaaaaaa aaagaaggaa gcctatctga ctattgcttc tcccccgcca 1560  
tccttcttac agcgtaaaaa gtgttggatgg agagaaatgt acagaagggg taactggctc 1620  
tgtctggggc cgaggaaagg cttcccgaaag gaggtaaaatt ttcaagctaaa cttctcagga 1680  
tgttagagtgc ttccctccagt tggggagag agagaggagg atatttcagg tgaagcgaac 1740  
agctttcccc gctgaccctg tggtaagttt cccaggggct ctacggcgaa ggttccccag 1800  
aggaaggat cttccataact tcaatgaggc actttaagaa acccttgagt tcagctggaa 1860  
ttcagacctt ccagagctac cagaaaaaca tcatgtggga aattgtgccc ggcgcgggtgt 1920  
cacgcctgta atccacgcac ttggggaggc cgaggcgggc ggttgcacgag gtcaggagat 1980  
cgagaccaac ctggctaaca tggtaaaacc ccatctctac tacaacgtt aaaaatcagc 2040  
cagggtgtggt ggcaggggcc tggtagtccca gctactgggg aggctgaggc aggggaatgg 2100  
cgtgaacctg ggaggcagag attgcagtga gctgagatca tgccactgca ctcgacagag 2160  
gcgaactccg tctcaaaaaa aaaaaaaaaaa aaagcgtcat gtggaaatg gttttccag 2220

3

cctccctgttag gggccgctgc tgccccagac tcagccagtc ttgtctaaga aaactcagag 2280  
gacgtctctg ctgggggtggt ggtggggtaac accctggacc tgccgccatc caaggagtga 2340  
acttaaggc gacagtgc ccaagcctga agaatatgca ctcagtcaat ggcattttgg 2400  
ggtagggagg gggtgttagtg ggcactgata ttttcagtc tctgggtcac cacaagttta 2460  
ttaaaaataaa agaaaaatgtg gtaaatgtc gccatctgtc ctgtccctac tcccaataca 2520  
cacacacagg cacacacaca cacaggcaca cacacacaca ggcacacata tacacacaca 2580  
cacacacaca cacacacaca cacacacaca cacacacacg cataacaaat caggtcccag 2640  
actagatgca ggagttgaaa ctgctttaaa acactctaag aacttaacta caaaccacaca 2700  
ctccccatgc ttctgggct taagatctt gagctcatc ttcagcatct ctccacgaga 2760  
aagtggggtg ggctgctcca tgaggtggag gtgaagaccc ctgagtctgc cccgtggagg 2820  
gggaggcccc ctaagcctag agtcccctg cagggctctg tgccaggagc ccccgtagc 2880  
catggcctcg aaagggcagc ggtgattttt ttcacataaa tatatgcac ttaaatgagt 2940  
ttagacagca tgacatcaga gagaattaa attggtttg gtggattc cgtttcoaat 3000  
tcctgagttc aggtttgtaa aagatttttc tgagcacctg caggcctgtg agtgtgtgt 3060  
tgtgtgtgtg tgtgtgtgtg tgtgtgtgaa gtatttcac tgaaaaggat tcaaaactag 3120  
ggggaaaaaa aaactggagc acacaggcag cattacgcca ttcttccttc ttggaaaaat 3180  
ccctcagcct tatacaagcc tccttcaagc cctcagtcag ttgtgcagga gaaagggggc 3240  
ggttggctt ctcccttcaa gaacgagttt tttcagctg ctgactggag acggtgacacg 3300  
tctggataacg agagcatttc cactatggg ctggatacaa acacacaccc ggcagacttc 3360  
aagagtctca gactgaggag aaagccttc ttctgctgc tactgctgct gccgctgctt 3420  
ttgaaagtcc actcccttca tggttttcc tgccaaacca gaggcacctt tgctgctgcc 3480  
gctgttctct ttgggtgtcat tcagcggctg gccagaggat g 3521

&lt;210&gt; 2

&lt;211&gt; 36

&lt;212&gt; DNA

&lt;213&gt; HUMAN

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)..(36)

&lt;223&gt; Sense PCR primer OD corresponding to human MP52

cDNA sequence

&lt;400&gt; 2

atgaattccc atggacctgg gctggmakga mtggat

36

&lt;210&gt; 3

4

<211> 29  
<212> DNA  
<213> HUMAN

<220>  
<221> misc\_feature  
<222> (1)..(29)  
<223> Reverse PCR primer OID corresponding to human MP52  
cDNA sequence

<400> 3  
atgaattcga gctgcgysgg srcacagca

29

# INTERNATIONAL SEARCH REPORT

Internat Application No  
PCT/IB 99/01071

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C12N15/85 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HOTTEN G ET AL: "Cloning and expression of recombinant human growth/differentiation factor 5" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 204, no. 2, 28 October 1994 (1994-10-28), pages 646-652, XP002115693 cited in the application figure 1	1
Y	-----	2-11
X	WO 95 04819 A (BIOPH BIOTECH ENTW PHARM GMBH) 16 February 1995 (1995-02-16)	1
Y	Seq.Id.No.1	2-11
	-----	-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

27 September 1999

08/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Lonnoy, O

**INTERNATIONAL SEARCH REPORT**

Internal Application No	PCT/IB 99/01071
-------------------------	-----------------

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 03188 A (BIOPH BIOTECH ENTW PHARM GMBH ;HOETTEN GERTRUD (DE); POHL JENS (DE) 30 January 1997 (1997-01-30) Seq.Id.No.2	1
Y	---	2-11
X	WO 97 04095 A (MATSUMOTO TOMOAKI ;HOECHST JAPAN (JP); KIMURA MICHIO (JP); FUJINO) 6 February 1997 (1997-02-06) Seq.Id.No.1	1
Y	---	2-11
Y	SAMBROOK J ET AL: "MOLECULAR CLONING: A LABORATORY MANUAL, PASSAGE" MOLECULAR CLONING, 1987, page 2.114-2.117; 14.7-14.8 XP002115694 the whole document	2,3
Y	WO 98 23740 A (AKZO NOBEL NV ;DIJKEMA REIN (NL); DEN WIJNGAARD ARTHUR VAN (NL)) 4 June 1998 (1998-06-04) claim 5	4-11
Y	WO 97 15308 A (ZYMOGENETICS INC ;OSTEOSCREEN INC (US); UNIV TEXAS AT AUSTIN (US)) 1 May 1997 (1997-05-01) cited in the application page 5, paragraph 2; examples 2,4	4-11
	---	

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Internal Application No

PCT/IB 99/01071

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9504819	A 16-02-1995	DE 4420157 A AU 688362 B AU 7498694 A CA 2169171 A CN 1129013 A CZ 9600357 A EP 0713529 A HU 74271 A JP 9501053 T NZ 271376 A ZA 9405992 A		23-02-1995 12-03-1998 28-02-1995 16-02-1995 14-08-1996 17-07-1995 29-05-1996 28-11-1996 04-02-1997 24-04-1997 14-03-1995
WO 9703188	A 30-01-1997	DE 19525416 A AU 6615196 A EP 0837938 A JP 11509097 T		16-01-1997 10-02-1997 29-04-1998 17-08-1999
WO 9704095	A 06-02-1997	JP 9031098 A AU 704364 B AU 6530496 A CA 2224289 A CN 1196087 A EP 0866125 A HU 9901204 A NO 980300 A		04-02-1997 22-04-1999 18-02-1997 06-02-1997 14-10-1998 23-09-1998 28-07-1999 23-01-1998
WO 9823740	A 04-06-1998	AU 5558498 A EP 0937145 A		22-06-1998 25-08-1999
WO 9715308	A 01-05-1997	AU 706262 B AU 7471096 A CA 2235481 A CN 1201393 A CZ 9801153 A EP 0866710 A HU 9802319 A NO 981810 A PL 327617 A		10-06-1999 15-05-1997 01-05-1997 09-12-1998 16-12-1998 30-09-1998 01-02-1999 22-06-1998 21-12-1998